Colorectal cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004-2018.

Esophageal and gastric cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004

Dear GPCR Enthusiasts , Get ready for an exciting learning experience with our newly updated Principles of Pharmacology I & II  courses! We've refreshed the schedule and can’t wait for you to join us on these new dates. New Course Dates: Principles of Pharmacology I :  October 3, 10, 17, 24 (four sessions) Principles of Pharmacology II :  October 31, November 7, 14, 21, December 5 (five sessions) Courses Highlights Act Fast: Don’t miss this incredible opportunity to immerse yourself in the  Principles of Pharmacology I & II BUNDLE . Grab this chance to deepen your understanding of pharmacology and take your knowledge to the next level! Secure your spot today and elevate your expertise! Premium members enjoy a 5-day free trial—join now and save with the 25% OFF early bird discount . Enrollment is now open to the public! Topics include pharmacologic activity measurement, mechanisms of action, and GPCR discovery strategies. Take advantage of a 25% early bird discount for premium members! Topics cover new cellular assays, real-time kinetics, and unique GPCR behaviors. Secure your spot now by signing up today! Did you know...? As a  premium member , you can access over 500 minutes of exclusive, expert-led content from esteemed leaders, Drs. Kenakin and Hoare . We highly recommend exploring valuable resources such as ' Applying Pharmacology to Drug Discovery ' and ' Advanced Data Analysis for GPCR Pharmacology' ." GPCR Event Spotlight    11th Adhesion GPCR Workshop    Location:  Mexico City Dates:  October 23-25, 2024 Connect with peers and delve into cutting-edge adhesion GPCR biology. Interested in boosting your brand? Reach out to us at Hello@DrGPCR.com for sponsorship opportunities .  Let’s dive into the   Classified GPCR News  from August 19th to 25th, 2024 GPCR Activation and Signaling Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling GPCR Binders, Drugs, and more Selenomethionine Promotes Milk Protein and Fat Synthesis and Proliferation of Mammary Epithelial Cells through the GPR37-mTOR-S6K1 Signaling GPCRs in Neuroscience Astrocyte Gi-GPCR signaling corrects compulsive-like grooming and anxiety-related behaviors in Sapap3 knockout mice Methods & Updates in GPCR Research Genome-wide identification of 769 G protein-coupled receptor (GPCR) genes from the marine medaka Oryzias melastigma Industry News Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project Ambrosia lands $16m to ‘improve on existing GLP-1 drugs’ Opening Ceremony of Xuzhou Zhongshu Research Site and CNS Drug Innovation Forum Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 Call for GPCR Papers NEW Emerging Voices in GPCR Biology in Special Issue of Molecular Pharmacology GPCR Events, Meetings, and Webinars September 5 - 6, 2024 | 4th Transatlantic ECI GPCR Symposium September 18, 2024 | FREE Webinar - The value of GPCR cell-based assays in drug discovery NEW September 30 - October 3, 2024 | 22nd Discovery on Target October 2024 | Biologics US 2024   October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry October 17, 2024 | Unprecedented fragment-based screening using Spectral Shift for GPCRs October 23 - 25, 2024 | 11th Adhesion GPCR Workshop November 5 - 7, 2024 | 16th Annual PEGS Europe   July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs NEW Research Associate Postdoc in GPCR mechanosensing   Postdoctoral Position Postdoctoral research position Senior or Lead Researcher   Become a Premium Member! Get your 5-day free trial TODAY!

< GPCR News < GPCRs in Oncology and Immunology Esophageal and gastric cancer incidence trends in Golestan The age-standardized incidence rates (ASRs) were calculated and presented per 100 000 person-years. We found significant decreasing trends in incidence rates of EC (EAPC = -5.0; 95% CI: -7.8 to -2.2) and less marked nonsignificant trends for GC (EAPC = -1.4; 95% CI: -4.0 to 1.4) during 2004 to 2018. Despite favorable trends, this population remains at high risk of both EC and GC.

Report an Incident Thank you for taking the time to report any incidents or issues you are experiencing Who is submitting this incident? First Name Last Name Email Details about this incident Please describe your concern Link to the page

One-year cumulative incidence functions were calculated based on time to first respiratory infection